Mahmoud Mahmoudian, PhD, FRSC
Business Development, Strategic Alliances
Dr. Mahmoudian is a Global Bio-Pharmaceutical Executive with a diverse career in both big pharma (AZ, GSK, and Merck) and entrepreneurial biotech settings, including emerging markets. He advances corporate development and research strategies by identifying external assets that complement an internal pipeline.
|
|
Dr. Mahmoudian has broad experience building and leading multi-national research and due diligence teams to identify, evaluate, recommend, and negotiate external opportunities in products, technology platforms, or companies as acquisition targets in multi-million dollar deals.
Dr. Mahmoudian’s career spans 20 years in the biotechnology, pharmaceutical, and chemical sectors. He joined Merck & Co. in 2007 with responsibility for External Partnerships in Vaccines & Biologics on a global basis. Prior to that, he was at Rohm & Haas as the Global Director of Biotechnology with responsibility for all strategic alliances and research in five sites (UK, France, Japan, China, USA) generating $600M sales. Dr. Mahmoudian recruited to Eastman earlier in his career as the Worldwide Head of Biotechnology responsible for R&D, alliances, and managing growth and development of its BioProducts portfolio. He launched his career with GlaxoSmithKline, where he held a variety of research, technology, and management roles of increasing responsibility in drug discovery and preclinical development.
Dr. Mahmoudian's key accomplishments include:
- Establishing two biotech startups, at Eastman and Rohm & Haas, via partnerships, alliances, and joint ventures (Genencor and Sanofi-Aventis). Dr. Mahmoudian was a member of the CEO team that recommended divestiture of Genencor to Danisco for $475M.
- Serving as a Principal Investigator at GlaxoSmithKline on internal and in-licensed compounds for key strategic alliances that led to the discovery and development of six blockbusters with combined annual sales of $15B (Lamuvidine®, anti-hepatitis; Epivir® and Abacavir®, anti-HIV; Relenza®, anti-flu; Zygara®, anti-leukaemic; and tribactam antibiotics)
- Acting as an advisor to top international biopharma and life sciences venture capital firms on topics that include investment and research strategies, due diligence, business plans, portfolio analysis, and technology / market assessments.
Dr. Mahmoudian earned his M.Sc. and Ph.D. in Biotechnology from Imperial College at the University of London, UK and was awarded a B.Sc. in Biochemistry / Human Physiology from the University of Newcastle, UK. He currently serves on the International Editorial Advisory Board of seven scientific journals and is a Board member of the European Federation on Biotechnology. Dr. Mahmoudian is an elected Fellow of the Royal Society of Chemistry (FRSC) and has >50 publications and patents to his name.
Dr. Mahmoudian is a British citizen and a permanent resident of the US. He and his family reside in Blue Bell, Pennsylvania. A former marathoner, he now enjoys the active arts community in Philadelphia.
|
